COO heads into Q1 earnings with revenue seen up 6.3% and EPS up 12%, as lens growth and cost savings face mix and tariff headwinds.
Get a deeper insight into the potential performance of The Cooper Companies (COO) for the quarter ended January 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
The Cooper Companies (COO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Albert G. White CEO | XMEX Exchange | US2166485019 ISIN |
| US Country | 16,000 Employees | 26 Jul 2023 Last Dividend | 20 Feb 2024 Last Split | - IPO Date |
The Cooper Companies, Inc., established in 1958 and headquartered in San Ramon, California, is a global entity that specializes in the development, manufacture, and marketing of contact lenses through its subsidiaries. The operations of the company are segmented into CooperVision and CooperSurgical. CooperVision focuses on providing a variety of contact lenses including those for correcting nearsightedness, farsightedness, astigmatism, presbyopia, and myopia across various regions such as the Americas, Europe, Middle East, Africa, and Asia Pacific. On the other hand, CooperSurgical addresses family and women's health, offering a wide range of fertility products and services, medical devices, contraception, and cryostorage services for cord blood and tissue to healthcare professionals and patients globally. The products offered by The Cooper Companies, Inc. reach their end-users through distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals, clinics, and authorized resellers.
CooperVision:
CooperSurgical: